Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. - Test2 - elhamkhani - TriplyDB

Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

http://www.wikidata.org/entity/Q35182164

about

Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discovery Nicotinic acetylcholine receptor ligands, a patent review (2006-2011)Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor Contrasting properties of α7-selective orthosteric and allosteric agonists examined on native nicotinic acetylcholine receptors Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptors Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Photoaffinity Labeling of Pentameric Ligand-Gated Ion Channels: A Proteomic Approach to Identify Allosteric Modulator Binding Sites.Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Insights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutations The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels.Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of α7 nicotinic acetylcholine receptors.Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures The minimal pharmacophore for silent agonism of the α7 nicotinic acetylcholine receptor.Changes in temperature have opposing effects on current amplitude in α7 and α4β2 nicotinic acetylcholine receptors.Merging old and new perspectives on nicotinic acetylcholine receptors Bilirubin modulates acetylcholine receptors in rat superior cervical ganglionic neurons in a bidirectional manner.Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.Structurally similar allosteric modulators of α7 nicotinic acetylcholine receptors exhibit five distinct pharmacological effects.Subunit interfaces contribute differently to activation and allosteric modulation of neuronal nicotinic acetylcholine receptors.Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation.Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.An Accessory Agonist Binding Site Promotes Activation of α4β2* Nicotinic Acetylcholine Receptors.Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.Menthol Enhances the Desensitization of Human α3β4 Nicotinic Acetylcholine Receptors.The influence of allosteric modulators and transmembrane mutations on desensitisation and activation of α7 nicotinic acetylcholine receptors Ligand Binding at the 4-4 Agonist-Binding Site of the 42 nAChR Triggers Receptor Activation through a Pre-Activated Conformational State.A Novel α2/α4 Subtype-selective Positive Allosteric Modulator of Nicotinic Acetylcholine Receptors Acting from the C-tail of an α Subunit Activation of α7 nicotinic receptors by orthosteric and allosteric agonists: influence on single-channel kinetics and conductance Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.Nicotinic acetylcholine receptors modulate osteoclastogenesis Activation of the α7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT₁a receptor antagonist.The Antinociceptive and Antiinflammatory Properties of 3-furan-2-yl-N-p-tolyl-acrylamide, a Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptors in Mice Photolabeling a Nicotinic Acetylcholine Receptor (nAChR) with an (α4)3(β2)2 nAChR-Selective Positive Allosteric Modulator.In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model.

P2860

Q26774830-83FDDFB9-3C41-49D4-B69F-4CF48A666316 Q26799689-E177A09F-7735-435D-BC46-438EF508A7EE Q26824360-9497396B-430C-4CAF-8072-9A39DE818BA7 Q27693356-451D910A-D057-421B-A8C6-35CDB9B22358 Q28076907-20E08129-549C-4703-A8AB-F20F1BC1CA15 Q28289112-1A772B90-5E49-4779-9D2A-750DD9B66C68 Q28485342-63CF0646-7BD8-459E-8DFE-71D734564F66 Q28655994-C9044088-3D24-4FC8-ACA6-EC2A47B0A78E Q30372351-52C50F8C-88B9-45AD-85DF-D90D58AB7D60 Q30381001-138EE12C-9046-46FF-8520-86C50CCB74F4 Q30402002-ED13565C-C827-4798-A0FB-CC4B2A6DC168 Q30428422-12748D9F-8D5E-4904-A0F8-969AE6DAEAB2 Q30448803-19C5A1A9-2E42-438A-828E-9D587AD6CEBD Q30486732-857987FE-33A0-4E64-A3A6-48C0969E377F Q30570721-97BBAF62-B372-4E2F-8381-44E3902D7E83 Q33353989-76535A16-D196-4530-BFEB-6C6398DDD1E7 Q34125095-F3928E16-F7E1-430A-8D4F-807F923F896F Q34168556-1152C61F-E8C6-4935-9FEE-7276760DCE16 Q34401492-9EE5FEBC-3F75-4EB4-842E-512FA552000D Q34698877-B7ED77D9-7B2D-4C23-8C8C-6639DC35B84F Q34870758-51B7CEF7-1B9E-400D-B349-F6D2274807AA Q35055568-A0B63DAD-B6ED-4992-8D8D-CEC085CD2623 Q35095077-A9170585-66B8-44E7-A768-6596AC536C73 Q35224319-1D7047E8-7D54-4A7E-829F-D5F3A1F5E458 Q35580546-9BC304BA-317C-4D99-A4B6-0E8994832C68 Q35586093-0ACA6A6F-5426-41B3-AA4C-22C7BE3D7D40 Q35662305-277EC348-F839-4648-99FF-7D3E1A161AF6 Q35745950-397230BB-CB6C-4508-97EC-158C51569449 Q35897852-682F9293-968D-4344-9656-F6D1155E810D Q35993539-86CE8E25-3636-4EF6-AE76-BCDD558284AF Q36110375-87617101-7A1E-4F35-B44C-FE8275A778B4 Q36323450-A87CA09D-8B31-4108-A167-F3BCC8BA262A Q36335581-2AA4352D-D639-421A-B2A2-6080BA193F1B Q36394997-D590F6DA-B87F-4196-8C1A-2BB544EC180E Q36650296-78C94524-E3D2-4949-ADF6-F1CAAF173AF7 Q36680435-2EDC9D02-1744-4936-A385-3A4B24F37E24 Q36807622-E0983BE8-66BC-4A30-897F-FD6353413470 Q36842788-777C338C-8A8A-46F2-BBD9-E0828BFE6D60 Q36852497-23481A8D-2A25-4607-B269-FAF14E93AEAF Q36929434-43EBDD37-794C-4887-9516-9A1ADF52C6A6

P2860

Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

http://www.wikidata.org/entity/Q35182164

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Positive allosteric modulators ...... s: advantages and limitations.

@ast

Positive allosteric modulators ...... s: advantages and limitations.

@en

type

label

Positive allosteric modulators ...... s: advantages and limitations.

@ast

Positive allosteric modulators ...... s: advantages and limitations.

@en

prefLabel

Positive allosteric modulators ...... s: advantages and limitations.

@ast

Positive allosteric modulators ...... s: advantages and limitations.

@en

P1433

Q35182164-79C59035-4BFB-4517-8E6B-191020DE11A5

P1476

Q35182164-1A4E54B1-CEE9-49AD-B2B8-94AF0B68A9A0

P2093

Q35182164-897A512D-A187-4FFE-96A7-9EA00C109F1E

Q35182164-927728B6-8A4E-4492-8308-8240C2877BB4

Q35182164-DDDD2773-C9AE-4D24-AF40-3940A9B49E83

P2860

Q35182164-029F5D19-4DD4-4751-8233-D1D3394B3C23

Q35182164-039574CD-2BDA-42F2-84C3-5E16A72B3094

Q35182164-03B49267-24D2-4B55-AD23-A673ECA3B882

Q35182164-046ECEED-FF79-4283-BB87-2D1723F080AC

Q35182164-04DEBCE0-3B83-402A-BE3D-623453909AD4

Q35182164-053AFF3C-DFC8-4A58-8F4D-0CC289669AE2

Q35182164-065D747C-34BF-4A76-82F4-CF3DF24C19F4

Q35182164-067163F5-9A39-45D7-8A89-BC34BB6C2ECF

Q35182164-06B2F1C9-F1E3-45AC-B192-5A650941D96A

Q35182164-0B204F75-19EE-431C-BC66-69AF43EE8010

P304

Q35182164-93771730-1190-423C-B981-19242FC5E6CF

P31

Q35182164-BB273095-F718-4C93-A65F-4A9DB374834A

P356

Q35182164-4168A185-16A1-43AA-9426-BFB2D5F0EE8B

P407

Q35182164-386DB921-BC05-4A19-BD36-DD22AD6A958E

P433

Q35182164-6E813307-853A-465F-B5BB-622CF0F14116

P478

Q35182164-4216FAED-8463-4C22-A1DD-990DA814EF2B

P577

Q35182164-A77C8AD6-1252-45E8-88EF-186C7C540C59

P5875

Q35182164-5B3A35F9-878C-4F3C-90F4-EA7848137CAA

P698

Q35182164-4D73423C-E35A-4929-8BB3-D46CAD26C4AE

P932

Q35182164-533F9F05-8A8F-4ED6-82CC-0901441E89C0

P356

J.BCP.2011.05.001

P1433

Biochemical Pharmacology

P1476

Positive allosteric modulators ...... s: advantages and limitations.

@en

P2093

Dustin K Williams

http://www.w3.org/2001/XMLSchema#string

Jingyi Wang

http://www.w3.org/2001/XMLSchema#string

Roger L Papke

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda

Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator

The positive allosteric modulator morantel binds at noncanonical subunit interfaces of neuronal nicotinic acetylcholine receptors

Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors

Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators

Galanthamine and Non-competitive Inhibitor Binding to ACh-binding Protein: Evidence for a Binding Site on Non-α-subunit Interfaces of Heteromeric Neuronal Nicotinic Receptors

X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel

ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL

P304

915-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BCP.2011.05.001

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51129960

http://www.w3.org/2001/XMLSchema#string

P698

21575610

http://www.w3.org/2001/XMLSchema#string

P932

3162128

http://www.w3.org/2001/XMLSchema#string